Physician profile
Claudia Char
NPI 1194449256
$6,658.18
in general payments reported to CMS, 2019-2025
24 companies · $3,922 in 2025
The $3,922 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $221 · 2023: $1,425 · 2024: $1,090 · 2025: $3,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,437.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,067.46 | 2023-2025 | Tremfya |
| Incyte Corporation | $843.76 | 2023-2025 | Opzelura, Opzelura |
| Pfizer INC. | $701.16 | 2022-2025 | |
| Ucb, INC. | $495.55 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $492.56 | 2022-2025 | Dupixent, Libtayo |
| Abbvie INC. | $473.99 | 2023-2025 | |
| Genzyme Corporation | $334.38 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $306.27 | 2023-2024 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $283.50 | 2025 | Nemluvio, Aklief, Dysport |
| Arcutis Biotherapeutics, INC. | $273.00 | 2024-2025 | Zoryve |
| Revance Therapeutics, INC. | $252.51 | 2025 | Daxxify, Daxi |
| Journey Medical Corporation | $250.81 | 2023-2025 | Emrosi |
| Leo Pharma INC. | $163.33 | 2024-2025 | Anzupgo, Adbry |
| Krystal Biotech INC | $124.80 | 2023 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.34 | 2025 | Spevigo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $99.84 | 2022 | |
| Janssen Scientific Affairs, LLC | $79.48 | 2024 | Tremfya |
| Botanix Sb INC | $62.39 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $58.97 | 2025 | |
| Almirall LLC | $53.91 | 2025 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.90 | 2023-2025 | Cabtreo, Jublia, Arazlo |
| Organon LLC | $31.29 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $25.58 | 2025 | Sotyktu |
| Ani Pharmaceuticals, INC. | $23.40 | 2025 | Oxistat |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Char listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.